CA
NZ
UK
AU
IND
US
Aditxt, Inc. (NASDAQ: ADTX) plunged nearly 15 per cent on Tuesday to $0.1010, as shareholders absorbed the implications of a Nasdaq Staff Determination letter that brought the company to the edge of a potentially terminal regulatory cliff. The disclosure confirmed what the share price …
Longeveron Inc. (NASDAQ: LGVN) barely moved on Tuesday, edging up just 0.59 per cent to $0.8502, in a muted market response to a regulatory development that, in a different sentiment environment, might have been expected to hit the stock considerably harder. The company disclosed …
A rodent-borne pathogen that rarely attracts mainstream financial attention is now driving material moves in aNasdaq-listed biotech. Traws Pharma (NASDAQ: TRAW) announced on May 8, 2026, plans to identify and advance clinical candidates targeting hantavirus infections. Shares closed up 28% at USD 2.18, extending …
A hantavirus outbreak that began quietly in the South Atlantic has now reached American soil, reigniting market interest in infectious disease countermeasures and placing a little-known rodent-borne pathogen under mainstream financial scrutiny.
Pharming Group, the Netherlands-based rare disease specialist best known for RUCONEST — its recombinant C1 esterase inhibitor for hereditary angioedema — issued full-year 2026 revenue guidance of $405 million to $425 million on Friday, a range that straddled analyst consensus of $411.9 million but …
Atara Biotherapeutics received perhaps the most consequential piece of regulatory clarity in its corporate history on Friday, as the US Food and Drug Administration confirmed — following a Type A meeting — that a single-arm study supported by an appropriate historical control could serve …
Entrada Therapeutics reported what it described as a statistically significant and potentially differentiated improvement versus placebo in Time to Rise velocity from its Phase 1/2 ELEVATE-44-201 trial of ENTR-601-44 in patients with Duchenne muscular dystrophy carrying exon 44-amenable mutations — and watched its shares …
EDAP TMS delivered a first-quarter performance that demonstrated the commercial momentum of its Focal One robotic high-intensity focused ultrasound platform in convincing terms, reporting record HIFU revenues of $11.6 million — a 78% year-over-year increase — alongside compelling clinical data from the HIFI-2 study. …
AIM ImmunoTech reported Phase 2 topline data for Ampligen (rintatolimod) in recurrent ovarian cancer that, on their face, represent some of the most clinically striking results the company has generated in its long and often turbulent history. A 50% objective response rate, a 79% …
enGene Therapeutics delivered a data readout on Friday that the market received as a decisive disappointment, sending shares down 81% to close at $1.72 after the company reported six-month complete response rates from the LEGEND Phase 2 pivotal cohort evaluating detalimogene voraplasmid in patients …
Please wait processing your request...